T1	Participants 116 153	sentinel lymph node-positive patients
T2	Participants 939 1075	Patients with SLN+ primary breast cancer were randomized for cALND (arm A, standard treatment) or RNI (arm B, investigational treatment)
T3	Participants 1252 1304	Between August 2002 and June 2009, 474 SLN+ patients
